Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NanoViricides, Inc is a biotechnology business based in the US. NanoViricides shares (NNVC) are listed on the NYSE MKT and all prices are listed in US Dollars. NanoViricides employs 17 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$3.59|
|52-week range||$2.85 - $6.49|
|50-day moving average||$4.26|
|200-day moving average||$4.31|
|Wall St. target price||$14.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.40|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-20.22%|
|3 months (2021-04-30)||-13.49%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-21.56%|
|Return on equity TTM||-37.33%|
|Market capitalisation||$48.1 million|
TTM: trailing 12 months
There are currently 718,556 NanoViricides shares held short by investors – that's known as NanoViricides's "short interest". This figure is 5.5% down from 760,031 last month.
There are a few different ways that this level of interest in shorting NanoViricides shares can be evaluated.
NanoViricides's "short interest ratio" (SIR) is the quantity of NanoViricides shares currently shorted divided by the average quantity of NanoViricides shares traded daily (recently around 115153.20512821). NanoViricides's SIR currently stands at 6.24. In other words for every 100,000 NanoViricides shares traded daily on the market, roughly 6240 shares are currently held short.
However NanoViricides's short interest can also be evaluated against the total number of NanoViricides shares, or, against the total number of tradable NanoViricides shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NanoViricides's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 NanoViricides shares in existence, roughly 60 shares are currently held short) or 0.0692% of the tradable shares (for every 100,000 tradable NanoViricides shares, roughly 69 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NanoViricides.
Find out more about how you can short NanoViricides stock.
We're not expecting NanoViricides to pay a dividend over the next 12 months.
NanoViricides's shares were split on a 1:20 basis on 23 September 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NanoViricides shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NanoViricides shares which in turn could have impacted NanoViricides's share price.
Over the last 12 months, NanoViricides's shares have ranged in value from as little as $2.85 up to $6.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while NanoViricides's is 0.8368. This would suggest that NanoViricides's shares are less volatile than average (for this exchange).
NanoViricides, Inc. , a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.